These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25375149)

  • 1. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
    Knutsvik G; Stefansson IM; Aziz S; Arnes J; Eide J; Collett K; Akslen LA
    PLoS One; 2014; 9(11):e112121. PubMed ID: 25375149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
    Muftah AA; Aleskandarany MA; Al-Kaabi MM; Sonbul SN; Diez-Rodriguez M; Nolan CC; Caldas C; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2017 Jul; 164(2):341-348. PubMed ID: 28478613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume.
    Focke CM; Decker T; van Diest PJ
    Ann Surg Oncol; 2017 May; 24(5):1251-1257. PubMed ID: 28008571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
    Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
    BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
    Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
    BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.
    Romero Q; Bendahl PO; Klintman M; Loman N; Ingvar C; Rydén L; Rose C; Grabau D; Borgquist S
    BMC Cancer; 2011 Aug; 11():341. PubMed ID: 21819622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
    Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
    Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Performance of Ki-67 Labeling Index in Different Specimen Categories of Invasive Ductal Carcinoma of the Breast Using 2 Scoring Methods.
    Al Nemer A
    Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):86-90. PubMed ID: 26509909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?
    Ahlin C; Aaltonen K; Amini RM; Nevanlinna H; Fjällskog ML; Blomqvist C
    Histopathology; 2007 Oct; 51(4):491-8. PubMed ID: 17711446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
    Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
    Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
    Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H
    Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer.
    Ruiz C; Seibt S; Al Kuraya K; Siraj AK; Mirlacher M; Schraml P; Maurer R; Spichtin H; Torhorst J; Popovska S; Simon R; Sauter G
    Int J Cancer; 2006 May; 118(9):2190-4. PubMed ID: 16331604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.
    Yamamoto S; Ibusuki M; Yamamoto Y; Fu P; Fujiwara S; Murakami K; Iwase H
    Breast Cancer; 2013 Jul; 20(3):262-70. PubMed ID: 22362219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens.
    Ahn S; Lee J; Cho MS; Park S; Sung SH
    Arch Pathol Lab Med; 2018 Mar; 142(3):364-368. PubMed ID: 29144790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations.
    Erices-Leclercq M; Lubig S; Förster F; Förster R; Baldus S; Rudlowski C; Schröder L
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):441-447. PubMed ID: 33991247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
    Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
    PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.